Today, the U.S. Food and Drug Administration approved Ryoncil (remestemcel-L-rknd), an allogeneic (donor) bone marrow-derived mesenchymal stromal cell (MSC) therapy indicated for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older.
![[Infographic] Môi trường nuôi cấy thế hệ thứ 3: CD AOF (Chemically Defined & Animal Origin Free)](https://biogroupvietnam.com/wp-content/uploads/2026/02/infographic-moi-truong-nuoi-cay-the-he-thu-3-cd-aof-200x150.png)
